486 related articles for article (PubMed ID: 24630730)
1. Synonymous mutations frequently act as driver mutations in human cancers.
Supek F; Miñana B; Valcárcel J; Gabaldón T; Lehner B
Cell; 2014 Mar; 156(6):1324-1335. PubMed ID: 24630730
[TBL] [Abstract][Full Text] [Related]
2. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations.
Diederichs S; Bartsch L; Berkmann JC; Fröse K; Heitmann J; Hoppe C; Iggena D; Jazmati D; Karschnia P; Linsenmeier M; Maulhardt T; Möhrmann L; Morstein J; Paffenholz SV; Röpenack P; Rückert T; Sandig L; Schell M; Steinmann A; Voss G; Wasmuth J; Weinberger ME; Wullenkord R
EMBO Mol Med; 2016 May; 8(5):442-57. PubMed ID: 26992833
[TBL] [Abstract][Full Text] [Related]
3. Silent mutations make some noise.
Zheng S; Kim H; Verhaak RGW
Cell; 2014 Mar; 156(6):1129-1131. PubMed ID: 24630716
[TBL] [Abstract][Full Text] [Related]
4. Defective pre-mRNA splicing in PKD1 due to presumed missense and synonymous mutations causing autosomal dominant polycystic disease.
Gonzalez-Paredes FJ; Ramos-Trujillo E; Claverie-Martin F
Gene; 2014 Aug; 546(2):243-9. PubMed ID: 24907393
[TBL] [Abstract][Full Text] [Related]
5. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene.
Aretz S; Uhlhaas S; Sun Y; Pagenstecher C; Mangold E; Caspari R; Möslein G; Schulmann K; Propping P; Friedl W
Hum Mutat; 2004 Nov; 24(5):370-80. PubMed ID: 15459959
[TBL] [Abstract][Full Text] [Related]
6. Depletion of somatic mutations in splicing-associated sequences in cancer genomes.
Hurst LD; Batada NN
Genome Biol; 2017 Nov; 18(1):213. PubMed ID: 29115978
[TBL] [Abstract][Full Text] [Related]
7. Somatic synonymous mutations in regulatory elements contribute to the genetic aetiology of melanoma.
Zhang D; Xia J
BMC Med Genomics; 2020 Apr; 13(Suppl 5):43. PubMed ID: 32241263
[TBL] [Abstract][Full Text] [Related]
8. Splicing defects caused by exonic mutations in PKD1 as a new mechanism of pathogenesis in autosomal dominant polycystic kidney disease.
Claverie-Martin F; Gonzalez-Paredes FJ; Ramos-Trujillo E
RNA Biol; 2015; 12(4):369-74. PubMed ID: 25757501
[TBL] [Abstract][Full Text] [Related]
9. Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs).
Gorlov IP; Gorlova OY; Frazier ML; Amos CI
Mutat Res; 2004 Oct; 554(1-2):175-83. PubMed ID: 15450416
[TBL] [Abstract][Full Text] [Related]
10. Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
Kouidou S; Malousi A; Maglaveras N
Mol Carcinog; 2009 Oct; 48(10):895-902. PubMed ID: 19367569
[TBL] [Abstract][Full Text] [Related]
11. Inferring Potential Cancer Driving Synonymous Variants.
Zeng Z; Bromberg Y
Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627162
[TBL] [Abstract][Full Text] [Related]
12. Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis.
Babenko VN; Basu MK; Kondrashov FA; Rogozin IB; Koonin EV
BMC Cancer; 2006 Feb; 6():36. PubMed ID: 16469093
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5' splice sites.
Sahashi K; Masuda A; Matsuura T; Shinmi J; Zhang Z; Takeshima Y; Matsuo M; Sobue G; Ohno K
Nucleic Acids Res; 2007; 35(18):5995-6003. PubMed ID: 17726045
[TBL] [Abstract][Full Text] [Related]
15. Exonic splice regulation imposes strong selection at synonymous sites.
Savisaar R; Hurst LD
Genome Res; 2018 Oct; 28(10):1442-1454. PubMed ID: 30143596
[TBL] [Abstract][Full Text] [Related]
16. Detection of somatic TP53 splice site mutations in diffuse astrocytomas.
Uno M; Oba-Shinjo SM; de Aguiar PH; Leite CC; Rosemberg S; Miura FK; Junior RM; Scaff M; Nagahashi Marie SK
Cancer Lett; 2005 Jun; 224(2):321-7. PubMed ID: 15914282
[TBL] [Abstract][Full Text] [Related]
17. Non-synonymous, synonymous, and non-coding nucleotide variants contribute to recurrently altered biological processes during retinoblastoma progression.
Stachelek K; Harutyunyan N; Lee S; Beck A; Kim J; Xu L; Berry JL; Nagiel A; Reynolds CP; Murphree AL; Lee TC; Aparicio JG; Cobrinik D
Genes Chromosomes Cancer; 2023 May; 62(5):275-289. PubMed ID: 36550020
[TBL] [Abstract][Full Text] [Related]
18. Novel p53 splice site mutations in three families with Li-Fraumeni syndrome.
Verselis SJ; Rheinwald JG; Fraumeni JF; Li FP
Oncogene; 2000 Aug; 19(37):4230-5. PubMed ID: 10980596
[TBL] [Abstract][Full Text] [Related]
19. Nonclassical splicing mutations in the coding and noncoding regions of the ATM Gene: maximum entropy estimates of splice junction strengths.
Eng L; Coutinho G; Nahas S; Yeo G; Tanouye R; Babaei M; Dörk T; Burge C; Gatti RA
Hum Mutat; 2004 Jan; 23(1):67-76. PubMed ID: 14695534
[TBL] [Abstract][Full Text] [Related]
20. Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications.
Soussi T; Taschner PE; Samuels Y
Hum Mutat; 2017 Apr; 38(4):339-342. PubMed ID: 28026089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
